{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:53:33Z","timestamp":1793832813407,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bcp.2024.116194","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T18:44:24Z","timestamp":1712342664000},"page":"116194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-0618","authenticated-orcid":false,"given":"Jun","family":"Sang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Cong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ji","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Yun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Ni","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116194_b0005","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bcp.2024.116194_b0010","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euf.2019.10.017","article-title":"Neoadjuvant therapies for bladder cancer in cisplatin-ineligible patients: what options do we have?","volume":"6","author":"Basu","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.bcp.2024.116194_b0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrurol.2011.144","article-title":"Urothelial carcinoma of the bladder: definition, treatment and future efforts","volume":"8","author":"Prasad","year":"2011","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bcp.2024.116194_b0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clgc.2013.11.016","article-title":"Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer","volume":"12","author":"Sonpavde","year":"2014","journal-title":"Clin. Genitourin. Canc."},{"key":"10.1016\/j.bcp.2024.116194_b0025","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1021\/acs.biochem.8b00307","article-title":"Targeting dependency on the GPX4 lipid peroxide repair pathway for cancer therapy","volume":"57","author":"Liu","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2024.116194_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216119","article-title":"Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience","volume":"559","author":"Lee","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2024.116194_b0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2018.09.014","article-title":"Role of GPX4 in ferroptosis and its pharmacological implication","volume":"133","author":"Seibt","year":"2019","journal-title":"Free Radical Bio. Med."},{"key":"10.1016\/j.bcp.2024.116194_b0040","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.freeradbiomed.2009.05.012","article-title":"Glutathione peroxidase 4 differentially regulates the release of apoptogenic proteins from mitochondria","volume":"47","author":"Liang","year":"2009","journal-title":"Free Radical Bio. Med."},{"key":"10.1016\/j.bcp.2024.116194_b0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116194_b0050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nchembio.2079","article-title":"Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis","volume":"12","author":"Shimada","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2024.116194_b0055","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.bmcl.2011.09.047","article-title":"Development of small-molecule probes that selectively kill cells induced to express mutant RAS","volume":"22","author":"We\u00efwer","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2024.116194_b0060","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.14654","article-title":"Depletion of PSMD14 suppresses bladder cancer proliferation by regulating GPX4","volume":"11","author":"Jia","year":"2023","journal-title":"PeerJ"},{"key":"10.1016\/j.bcp.2024.116194_b0065","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.3390\/ijms24065144","article-title":"Jia Guo, HSPA5 promotes the proliferation, metastasis and regulates ferroptosis of bladder cancer","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116194_b0070","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41419-021-04306-2","article-title":"Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells","volume":"12","author":"Sun","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2024.116194_b0075","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","article-title":"Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer","volume":"81","author":"Ghoochani","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116194_b0080","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3389\/fphar.2018.01371","article-title":"Tian Xie, RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer","volume":"9","author":"Sui","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116194_b0085","first-page":"403","article-title":"Thioredoxin signaling pathways in cancer","volume":"38","author":"Zhang","year":"2023","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.bcp.2024.116194_b0090","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2013.07.036","article-title":"The thioredoxin antioxidant system","volume":"66","author":"Lu","year":"2014","journal-title":"Free Radic. Bio. Med."},{"key":"10.1016\/j.bcp.2024.116194_b0095","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.tips.2017.06.001","article-title":"Targeting the thioredoxin system for cancer therapy","volume":"38","author":"Zhang","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2024.116194_b0100","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.1021\/acs.jmedchem.8b01595","article-title":"Targeting the thioredoxin system as a strategy for cancer therapy","volume":"62","author":"Bian","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116194_b0105","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/med.21734","article-title":"Small molecules regulating reactive oxygen species homeostasis for cancer therapy","volume":"41","author":"Zhang","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2024.116194_b0110","doi-asserted-by":"crossref","unstructured":"Y. Yang, S. Sun, W. Xu, Y. Zhang, R. Yang, K. Ma, J. Zhang, J. Xu, Piperlongumine inhibits thioredoxin reductase 1 by targeting selenocysteine residues and sensitizes cancer cells to erastin, Antioxidants 2022 (710\u2212724).","DOI":"10.3390\/antiox11040710"},{"key":"10.1016\/j.bcp.2024.116194_b0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.freeradbiomed.2019.06.005","article-title":"Curcuminoid WZ26, a TrxR1 inhibitor, effectively inhibits colon cancer cell growth and enhances cisplatin-induced cell death through the induction of ROS","author":"Zhang","year":"2019","journal-title":"Free Radic. Bio. Med."},{"key":"10.1016\/j.bcp.2024.116194_b0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2021.03.030","article-title":"Jolkinolide B targets thioredoxin and glutathione systems to induce ROS-mediated paraptosis and apoptosis in bladder cancer cells","volume":"509","author":"Sang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2024.116194_b0125","article-title":"Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy","volume":"352\u2013362","author":"Sang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2024.116194_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2023.03.263","article-title":"Plumbagin is a novel GPX4 protein degrader that induces apoptosis in hepatocellular carcinoma cells","volume":"203","author":"Yao","year":"2023","journal-title":"Free Radical Bio. Med."},{"key":"10.1016\/j.bcp.2024.116194_b0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-020-01016-8","article-title":"Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells","volume":"14","author":"Dingm","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2024.116194_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101413","article-title":"AR ubiquitination induced by the curcumin analog suppresses growth of temozolomide-resistant glioblastoma through disrupting GPX4-mediated redox homeostasis","volume":"30","author":"Chen","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2024.116194_b0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.chembiol.2008.02.010","article-title":"Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells","volume":"15","author":"Yang","year":"2008","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2024.116194_b0150","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1073\/pnas.1908158117","article-title":"High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model","volume":"117","author":"Luchtel","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2024.116194_b0155","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.freeradbiomed.2018.10.426","article-title":"Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer","volume":"129","author":"Shin","year":"2018","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.bcp.2024.116194_b0160","doi-asserted-by":"crossref","first-page":"31189","DOI":"10.1073\/pnas.2017152117","article-title":"Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis","volume":"117","author":"Yi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2024.116194_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102426","article-title":"Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR\/SREBP-1\/SCD1-mediated lipogenesis in PIK3CA-mutatnt colorectal cancer","volume":"55","author":"Chen","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2024.116194_b0170","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41418-019-0352-3","article-title":"Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis","volume":"27","author":"Chen","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2024.116194_b0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41420-021-00468-2","article-title":"O-GlcNAcylation enhances sensitivity to RSL3-induced ferroptosis via the YAP\/TFRC pathway in liver cancer","volume":"7","author":"Zhu","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bcp.2024.116194_b0180","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","article-title":"FSP1 is a glutathione-independent ferroptosis suppressor","volume":"575","author":"Doll","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116194_b0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2024.116194_b0190","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116194_b0195","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/0008-5472.CAN-20-1488","article-title":"Frizzled-7 identifies platinum-tolerant ovarian cancer cells susceptible to ferroptosis","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116194_b0200","first-page":"4293","article-title":"Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide","volume":"55","author":"Yokomizo","year":"1995","journal-title":"Canc. Res."},{"key":"10.1016\/j.bcp.2024.116194_b0205","doi-asserted-by":"crossref","unstructured":"L. L. Cai, R. A. Ruberto, M. J. Ryan, J. K. Eaton, S. L. Schreiber, V. S. Viswanathan, Modulation of ferroptosis sensitivity by TXNRD1 in pancreatic cancer cells, bioRxiv (2020), https:\/\/doi.org\/10.1101\/2020.06.25.165647.","DOI":"10.1101\/2020.06.25.165647"},{"key":"10.1016\/j.bcp.2024.116194_b0210","doi-asserted-by":"crossref","first-page":"15410","DOI":"10.1021\/acs.jmedchem.0c01449","article-title":"Development of potential antitumor agents from the scaffolds of plant-derived terpenoid lactones","volume":"63","author":"Ren","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116194_b0215","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"G, M, Cragg, Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J Nat. Prod."},{"key":"10.1016\/j.bcp.2024.116194_b0220","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1039\/D2NP00047D","article-title":"Euphorbia diterpenoids: isolation, structure, bioactivity, biosynthesis, and synthesis (2013\u20132021)","volume":"39","author":"Zhan","year":"2022","journal-title":"Nat. Prod. Rep."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224001771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224001771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:24:07Z","timestamp":1728951847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":44,"alternative-id":["S0006295224001771"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116194","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116194"}}